Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions he has had with the Dementia Research Institute on the potential roll-out of Lecanemab to the NHS.

I have held no discussions.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources.

NICE has been asked by the Department to conduct an appraisal of lecanemab for treating early Alzheimer’s disease. The appraisal is anticipated to begin in late August 2023.